Non-alcoholic fatty liver disease therapeutic - Bioiberica
Latest Information Update: 28 Jul 2016
At a glance
- Originator Bioiberica
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Non-alcoholic fatty liver disease
Most Recent Events
- 28 Jul 2016 Clinical trials in Non-alcoholic fatty liver disease in Spain (unspecified route)